
Page#1
nif ba1429101 33
3
3
A B B O T T 2 0 1 8  A N N U A L  R E P O R T
1
0
1
9
2
4
CONSOLIDATED STATEMENT OF EARNINGS
1
a
b
(in millions except per share data)
f
i
n
Year Ended December 31 2018 2017 2016
Net Sales $30,578 $27,390 $20,853
Cost of products sold, excluding amortization of intangible assets 12,706 12,409 9,094
Amortization of intangible assets 2,178 1,975 550
Research and development 2,300 2,260 1,447
Selling, general and administrative 9,744 9,182 6,736
Total Operating Cost and Expenses 26,928 25,826 17,827
Operating Earnings 3,650 1,564 3,026
Interest expense 826 904 431
Interest income (105) (124) (99)
Net foreign exchange (gain) loss 28 (34) 495
Debt extinguishment costs 167 — —
Other (income) expense, net (139) (1,413) 786
Earnings from Continuing Operations Before Taxes 2,873 2,231 1,413
Taxes on Earnings from Continuing Operations 539 1,878 350
Earnings from Continuing Operations 2,334 353 1,063
Earnings from Discontinued Operations, net of taxes 34 124 321
Gain on sale of Discontinued Operations, net of taxes — — 16
Net Earnings from Discontinued Operations, net of taxes 34 124 337
Net Earnings $÷2,368 $÷÷«477 $÷1,400
Basic Earnings Per Common Share —
Continuing Operations $÷÷1.32 $÷÷0.20 $÷÷0.71
Discontinued Operations 0.02 0.07 0.23
Net Earnings $÷÷1.34 $÷÷0.27 $÷÷0.94
Diluted Earnings Per Common Share —
Continuing Operations $÷÷1.31 $÷÷0.20 $÷÷0.71
Discontinued Operations 0.02 0.07 0.23
Net Earnings $÷÷1.33 $÷÷0.27 $÷÷0.94
Average Number of Common Shares Outstanding Used for Basic
Earnings Per Common Share 1,758 1,740 1,477
Dilutive Common Stock Options 12 9 6
Average Number of Common Shares Outstanding Plus Dilutive
Common Stock Options 1,770 1,749 1,483
Outstanding Common Stock Options Having No Dilutive Effect — — 5
The accompanying notes to consolidated financial statements are an integral part of this statement.
n
i
f
b
a
1
4
2
9
1
0
1
3
3
3 3
33 1019241ab fin
03.04.2019 18:19PM 1019241ab
8.500 in x 11.000 in Abbott Labs
K 2925
karenl (sa1) 1019241ab fin
amoore file://sanjfs5.sa1.com/Sandy/1019241ab
Page#2
nif ba1429101 53
3
5
A B B O T T 2 0 1 8  A N N U A L  R E P O R T
1
0
1
9
2
4
CONSOLIDATED STATEMENT OF CASH FLOWS
1
a
b
(in millions)
f
i
n
Year Ended December 31 2018 2017 2016
Cash Flow From (Used in) Operating Activities:
Net earnings $÷«2,368 $÷÷÷477 $ 1,400
Adjustments to reconcile earnings to net cash from operating activities —
Depreciation 1,100 1,046 803
Amortization of intangible assets 2,178 1,975 550
Share-based compensation 477 406 310
Impact of currency devaluation — — 480
Amortization of inventory step-up 32 907 —
Investing and financing losses, net 126 47 86
Loss on extinguishment of debt 167 — —
Amortization of bridge financing fees — 5 165
Gains on sale of businesses — (1,163) (25)
Mylan N.V. equity investment adjustment — — 947
Gain on sale of Mylan N.V. shares — (45) —
Trade receivables (190) (207) (177)
Inventories (514) 249 (98)
Prepaid expenses and other assets 23 109 113
Trade accounts payable and other liabilities 747 615 (652)
Income taxes (214) 1,149 (699)
Net Cash From Operating Activities 6,300 5,570 3,203
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment (1,394) (1,135) (1,121)
Acquisitions of businesses and technologies, net of cash acquired — (17,183) (80)
Proceeds from business dispositions 48 6,042 25
Proceeds from the sale of Mylan N.V. shares — 2,704 —
Purchases of investment securities (131) (210) (2,823)
Proceeds from sales of investment securities 73 129 3,709
Other 48 35 42
Net Cash From (Used in) Investing Activities (1,356) (9,618) (248)
Cash Flow From (Used in) Financing Activities:
Proceeds from issuance of (repayments of ) short-term debt and other (26) (1,034) (1,767)
Proceeds from issuance of long-term debt and debt with maturities
over 3 months 4,009 6,742 14,934
Repayments of long-term debt and debt with maturities over 3 months (12,433) (8,650) (12)
Payment of bridge financing fees — — (170)
Purchase of Alere preferred stock — (710) —
Acquisition and contingent consideration payments related to business
acquisitions — (13) (25)
Purchases of common shares (238) (117) (522)
Proceeds from stock options exercised 271 350 248
Dividends paid (1,974) (1,849) (1,539)
Net Cash From (Used in) Financing Activities (10,391) (5,281) 11,147
Effect of exchange rate changes on cash and cash equivalents (116) 116 (483)
Net Increase (Decrease) in Cash and Cash Equivalents (5,563) (9,213) 13,619
Cash and Cash Equivalents, Beginning of Year 9,407 18,620 5,001
Cash and Cash Equivalents, End of Year $÷«3,844 $÷«9,407 $18,620
Supplemental Cash Flow Information: n
i
f
Income taxes paid $÷÷÷740 $÷÷÷570 $ 620 b
a
1
Interest paid 845 917 181 4
2
9
1
0
The accompanying notes to consolidated financial statements are an integral part of this statement. 1
5
3
3 5
35 1019241ab fin
03.04.2019 18:19PM 1019241ab
8.500 in x 11.000 in Abbott Labs
K 2925
karenl (sa1) 1019241ab fin
amoore file://sanjfs5.sa1.com/Sandy/1019241ab
Page#3
nif ba1429101 63
3
6
A B B O T T 2 0 1 8  A N N U A L  R E P O R T
1
0
1
9
2
4
CONSOLIDATED BAL ANCE SHEET
1
a
b
(dollars in millions)
f
i
n
December 31 2018 2017
Assets
Current Assets:
Cash and cash equivalents $÷3,844 $÷9,407
Investments, primarily bank time deposits and U.S. treasury bills 242 203
Trade receivables, less allowances of — 2018: $314; 2017: $294 5,182 5,249
Inventories:
Finished products 2,407 2,339
Work in process 499 472
Materials 890 790
Total inventories 3,796 3,601
Other prepaid expenses and receivables 1,559 1,667
Current assets held for disposition 9 20
Total Current Assets 14,632 20,147
Investments 897 883
Property and Equipment, at Cost:
Land 501 526
Buildings 3,555 3,613
Equipment 10,756 10,394
Construction in progress 894 732
15,706 15,265
Less: accumulated depreciation and amortization 8,143 7,658
Net Property and Equipment 7,563 7,607
Intangible Assets, net of amortization 18,942 21,473
Goodwill 23,254 24,020
Deferred Income Taxes and Other Assets 1,868 1,944
Non-current Assets Held for Disposition 17 176
$67,173 $76,250
The accompanying notes to consolidated financial statements are an integral part of this statement.
n
i
f
b
a
1
4
2
9
1
0
1
6
3
3 6
36 1019241ab fin
03.04.2019 18:19PM 1019241ab
8.500 in x 11.000 in Abbott Labs
K 2925
karenl (sa1) 1019241ab fin
amoore file://sanjfs5.sa1.com/Sandy/1019241ab
Page#4
nif ba1429101 73
3
7
A B B O T T 2 0 1 8  A N N U A L  R E P O R T
1
0
1
9
2
4
CONSOLIDATED BAL ANCE SHEET
1
a
b
(dollars in millions)
f
i
n
December 31 2018 2017
Liabilities and Shareholders’ Investment
Current Liabilities:
Short-term borrowings $÷÷«200 $÷÷«206
Trade accounts payable 2,975 2,402
Salaries, wages and commissions 1,182 1,187
Other accrued liabilities 3,780 3,811
Dividends payable 563 489
Income taxes payable 305 309
Current portion of long-term debt 7 508
Total Current Liabilities 9,012 8,912
Long-term Debt 19,359 27,210
Post-employment obligations and other long-term liabilities 8,080 9,030
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value
Authorized — 1,000,000 shares, none issued — —
Common shares, without par value
Authorized — 2,400,000,000 shares
Issued at stated capital amount —
Shares: 2018: 1,971,189,465; 2017: 1,965,908,188 23,512 23,206
Common shares held in treasury, at cost —
Shares: 2018: 215,570,043; 2017: 222,305,719 (9,962) (10,225)
Earnings employed in the business 24,560 23,978
Accumulated other comprehensive income (loss) (7,586) (6,062)
Total Abbott Shareholders’ Investment 30,524 30,897
Noncontrolling Interests in Subsidiaries 198 201
Total Shareholders’ Investment 30,722 31,098
$67,173 $76,250
The accompanying notes to consolidated financial statements are an integral part of this statement.
n
i
f
b
a
1
4
2
9
1
0
1
7
3
3 7
37 1019241ab fin
03.04.2019 18:19PM 1019241ab
8.500 in x 11.000 in Abbott Labs
K 2925
karenl (sa1) 1019241ab fin
amoore file://sanjfs5.sa1.com/Sandy/1019241ab